DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by...

Full description

Saved in:
Bibliographic Details
Main Authors O´HEAR Carol, Elaine, LI Chi- Chung, BENDER Brendan, Christian
Format Patent
LanguageEnglish
Spanish
Published 25.05.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab). La presente invención se refiere al tratamiento de sujetos que tienen trastornos proliferativos celulares positivos para CD20 (por ejemplo, trastornos proliferativos de linfocitos B, tales como linfomas no hodgkinianos). Más específicamente, la invención se refiere al tratamiento de sujetos que tienen un trastorno proliferativo de linfocitos B mediante la administración intravenosa de un anticuerpo biespecífico anti-CD20/anti-CD3 (por ejemplo, mosunetuzumab).
Bibliography:Application Number: MX20230005132